Prescription drug · NDA
Nuplazid (Pimavanserin tartrate) NDC 63090-100
Pimavanserin tartrate 10 mg/1 · Tablet, Coated · Oral · Acadia Pharmaceuticals Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 63090-100-30 | 63090010030 | 30 TABLET, COATED in 1 BOTTLE, PLASTIC (63090-100-30)Marketed from Jun 28, 2018 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Nuplazid
- Generic name (nonproprietary)
- pimavanserin tartrate
- Active ingredients
- Pimavanserin tartrate — 10 mg/1
- Dosage form
- Tablet, Coated
- Route
- Oral
- Labeler
- Acadia Pharmaceuticals Inc.NDC labeler code 63090
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 207318
- Marketing start
- Listing expires
- Identifiers
- Product ID 63090-100_2199d74b-37ed-408c-97af-ef036899216bSPL ID 2199d74b-37ed-408c-97af-ef036899216bSPL set ID 1e6bea44-57d6-4bac-9328-46e1ee59f83bRxCUI 2049269, 2049271, 2049275, 2049278UNII NA83F1SJSRUPC 0363090100303, 0363090340303
- Pharmacologic class
- Atypical Antipsychotic
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N463090010030followed by a unit qualifier and the quantityPackage 63090-0100-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
NUPLAZID ® is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis [ see Clinical Studies (14) ] . NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 63090-100
- What is NDC 63090-100?
- 63090-100 is the product NDC for Nuplazid (pimavanserin tartrate), Pimavanserin tartrate 10 mg/1 tablet, coated, listed with the FDA by Acadia Pharmaceuticals Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Nuplazid (Pimavanserin tartrate).
- What is the active ingredient?
- Pimavanserin tartrate.
- Who is the labeler?
- Acadia Pharmaceuticals Inc., NDC labeler code 63090. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Nuplazid?
- 1 other product NDC are listed under this name. See all Nuplazid NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Nuplazid products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Nuplazidpimavanserin tartrate | Pimavanserin tartrate 34 mg/1 | CapsuleOral | Acadia Pharmaceuticals Inc. | 63090-340 | 63090-0340-30 |